Cognigen Corporation, a wholly owned subsidiary of Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of simulation and modeling software for pharmaceutical discovery and development, today announced that it has released Version 1.3 of KIWI™, a private, cloud-based platform to efficiently and consistently organize, process, evaluate, and communicate modeling and simulation results.
Mr. Andrew Rokitka, director of Information Technology at Cognigen, said, “The pharmaceutical industry has been rapidly adopting cloud technology as a solution to ever-expanding computer processing needs. Leveraging our 20-plus years of experience in providing an architecture supporting modeling and simulation efforts, we have developed KIWI as a secure, validated, enterprise-scale environment, enabling global teams to collaborate on model-based decision making.”
Ted Grasela, president of Cognigen and Simulations Plus, added, “KIWI has proven to be a valuable platform for encouraging interdisciplinary discussions about the model development process and interpretation of results. We continue to receive positive feedback about the functionality implemented in KIWI and the value of the approach we have taken to harness cloud technology. As Cognigen intends to continue to improve functionality and collaboration within the KIWI platform, the licensing fee will be a source of recurring revenue for further development and growth.”
Dr. Sebastien Bihorel, associate director, Pharmacometrics, added, “This version of KIWI provides our user community with access to new features that accelerate completion of modeling projects by decreasing run times and facilitating the comparison and exporting of results across models. These features include dynamic comparisons of model parameter estimates and diagnostic plots, export of model run records for regulatory submissions, and accelerated infrastructure with the upgrade to the latest versions of NONMEM® and Perl-speaks-NONMEM running in a 64-bit Linux environment.”